Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is about to enter a Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin). CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE) as well as Hamilton BioVentures and California Technology Partners.
View Top Employees from Ceregene , Inc.| Website | http://www.ceregene.com |
| Revenue | $3 million |
| Funding | $82.1 million |
| Employees | View employees |
| Address | 9381 Judicial Dr, Ste 130, San Diego, California 92121, US |
| Phone | (858) 458-8800 |
| Fax | (858) 458-8801 |
| Industry | Business Services General, Business Services |
| Competitors | Actinogen Medical, GQ Bio Therapeutics, GenSight Biologics, Neuraltus Pharmaceuticals, Vivet Therapeutics |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular Ceregene , Inc. employee's phone or email?
Ceregene , Inc. Questions
The Ceregene , Inc. annual revenue was $3 million in 2024.
Ceregene , Inc. is based in San Diego, California.
The NAICS codes for Ceregene , Inc. are [5417, 541714, 541, 54, 54171].
The SIC codes for Ceregene , Inc. are [87, 873].
Related Companies
